Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With β-Thalassemia

Next Previous
X
Search
Trial Profile

A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With β-Thalassemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use
  • Sponsors Acceleron Pharma

    • Most Recent Events

    • 17 Jun 2021 Results analyzing MCV variation as an early predictor of response to Luspatercept by using data from phase II/III clinical trials (NCT01749540, NCT02268409, NCT02604433, NCT03342404, NCT04064060) presented at the 26th Congress of the European Haematology Association
    • 12 Jul 2020 Data from patients with beta-thalassemia in 3 studies (NCT01749540, NCT02268409, NCT02604433) assessing population pharmacokinetics and exposure-response relationship of luspatercept in patients with beta-thalassemia under a titration-to-response dosing regimen published in the Journal of Clinical Pharmacology
    • 10 Jan 2019 According to an Acceleron Pharma media release, the journal Blood has published results from this trial. Antonio Piga was a lead author of the newly published study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top